TABLE 2.

Univariate analysis of LUSI and survival

	Disease-free survival			Overall survival
	Hazard ratio	95% CI	p	Hazard ratio	95% CI	p
Patient characteristics
Age	1.01	0.98–1.04	0.44	1.03	1.01–1.05	0.01
BMI	0.99	0.96–1.03	0.77	1.01	0.99–1.04	0.37
Racea	2.18	0.94–5.01	0.07	1.36	0.73–2.51	0.33
Adjuvant therapyb	1.35	0.61–2.99	0.46	1.17	0.69–1.99	0.55
Tumor characteristics
LUSI	2.46	1.19–5.08	0.02	1.75	1.12–2.76	0.01
Stage
IA vs. II	– c	– c	0.99	0.39	0.19–0.83	0.01
IB vs. II	0.54	0.22–1.30	0.17	0.55	0.30–0.99	0.05
IC vs. II	0.84	0.32–2.22	0.73	0.69	0.35–1.36	0.28
Grade
2 vs. 1	3.26	1.35–7.87	<0.01	1.65	1.00–2.72	0.05
3 vs. 1	7.71	3.15–18.87	<0.001	2.61	1.47–4.64	<0.01
LVSI	3.43	1.73–6.79	<0.001	1.67	1.04–2.68	0.03
MSI high	1.38	0.65–2.9	0.41	0.95	0.57–1.59	0.85

BMI body mass index, LUSI lower uterine segment involvement, LVSI lymphovascular space involvement, MSI microsatellite instability

^aReference category is “white”

^bReference category is “none”

^cUnable to estimate due to no events in category “IA”